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We investigated the eﬀects of implementation of an institution-wide screening and decolonization protocol on the rates of deep
surgicalsiteinfections (SSIs)inpatients undergoingprimarykneeandhiparthroplasties.2058patientswere enrolled in thisstudy:
1644 patients in the treatment group and 414 in the control group. The treatment group attended preoperative admission testing
(PAT) clinic where they were screened for MSSA and MRSA colonization. All patients were provided a 5-day course of nasal
mupirocin and a single preoperative chlorhexidine shower. Additionally, patients colonized with MRSA received Vancomycin
perioperative prophylaxis. The control group did not attend PAT nor receive mupirocin treatment and received either Ancef or
Clindamycin for perioperative antibiotic prophylaxis. There were a total of 6 deep infections in the control group (1.45%) and 21
inthe treatment group (1.28%);thisrepresented adecrease of13%(P = .809)inthe treatment versuscontrol group. This decrease
represented a positive trend in favor of staphylococcus screening, decolonization with mupirocin, and perioperative Vancomycin
for knownMRSA carriers.
1.Introduction
Prosthetic joint replacement is a reliable pain-relieving
procedure that is in increasing demand with the aging
population.Infections associated with prostheticjointscause
a signiﬁcant morbidity to the patient and a large burden
on the health care budget [1–3] .T h eu n i v e r s a lu s eo f
preoperativeantibioticsand laminarairﬂowin theoperating
room has reduced the number of infections associated with
primary prosthetic joint replacements to less than 2% [4].
The Centers for Disease Control’s National Nosocomial
Infections Surveillance (NNIS) system, reports that among
surgical patients surgical site infections (SSIs) are the most
common nosocomial infection, accounting for 38% of
all such hospital acquired infections [5–7]. Furthermore,
Staphylococcus aureus is the most commonly identiﬁed
pathogeninall SSIsat a rate of25% [5]. Methicillin-resistant
Staphylococcus aureus (MRSA) SSIs are an increasing health
problem in the United States [8]. According to one study,
57% of nosocomial infections with Staphylcoccus aureus are
resistant to methicillin [8]. The ecologic niche of S. aureus
is the anterior nares, and at any given time, 25% to 30% of
thepopulationiscolonized.Patientswho are colonizedare at
a 2 to 9 times higher risk for staphylococcal infections after
surgical procedures than are those noncolonized [9].
Mupirocin is a topical antibiotic that decolonizes the
anterior nares [3, 10]. Intranasal mupirocin prevents post-
operative Staphylococus aureus infections in patients that
were colonized with S. aureus prior to surgery [3]. In a
randomized, double-blinded study of orthopaedic patients
the use of mupirocin was found to reduce the rate of
endogenousS.aureus infections to 5 times lower than that of
the placebo group [11]. Recent literature has demonstrated
thecost-eﬀectivenessofuniversalS.aureusdetectioninhigh-
risk patient populations [3, 9, 11–13].
Weimplementedascreening, decolonization,andantibi-
otic prophylaxis protocol for all patients that have elective
surgery at our institution. The purpose of this study is to
compare the eﬀect of our MRSA decolonization protocol on
theratesofSSIsinpatientswhounderwentprimary kneeand
hip arthroplasties from 2007 to 2009 versus those patients
who did not follow this protocol.2 Arthritis
2.MaterialandMethods
2.1. Selection Criteria. All patients undergoing primary total
knee or total hip arthroplasty from November 2007 through
June 2009 at NYU Hospital for Joint Diseases were enrolled
in the study. Each patient was included once even if
bilateral surgeries were performed. Patients undergoing a
revision operation or nonprosthetic hip or knee surgery
were excluded from the study. All eligible patients that
attended preadmission testing clinic (PAT) at NYU-HJD
were considered part of the treatment arm. The remaining
eligible patients that did not attend preadmission testing
at NYU-HJD made up the control group. Both groups
underwent total joint surgery during the same time period.
TheIRBcommitteeatNYUSchoolofMedicineapprovedthe
study protocol.
2.2. Treatment. Patients in the treatment arm attended PAT
clinic within 30 days of their surgery. During the visit, swabs
of both nares were obtained and sent oﬀ to NYU microbiol-
ogy laboratory for routine cultures for the presence of staph
species. Irrespective of the culture result all patients that
went through PAT received a prescription for a 5-day course
of 2% Mupirocin nasal ointment and a single preoperative
chlorhexidine shower [5, 8, 9]. Nasal screening results were
available for all treated patients on the day of surgery, and
MRSApositivecarrierswere givenperioperativeVancomycin
1 gram every 12 hours starting at least 30 minutes before
incision and lasting for 24 hours. The MRSA/MSSA status
of the non-PAT control group was unknown and, therefore,
either Ancef or Clindamycin prophylaxis was administered.
Thesurgicaltechnique,implantsandpostoperativecarewere
similar in both groups. (See Figure 1).
2.3. Outcome. The primary outcome was the rate of SSI.
Secondary outcomes were the prevalence of MSSA/MRSA
in the study population, rate of SSIs due to S. aureus, and
the rate of endogenous S. aureus SSIs. All patients were
followed for one year for postoperative infection. SSIs were
classiﬁed using the Centers for Disease Control criteria [7].
Only deep incisional SSIs were considered clinically relevant
and considered in the analysis.
2.4. Statistical Analysis. Statistical analysis was performed
using Fisher’s exact test.
3.Results
During the study period, 2058 patients were included in
the study. There was complete followup in this retrospective
study of prospectively collected data. The total number of
treatment patients was 1644 patients (80%) and 414 (20%)
inthecontrol group.Atthe onset ofthestudy theproportion
ofthe PAT treatment group to the control group was roughly
equal. However, as the study progressed the protocol was
quickly adopted by all surgeons and the non-PAT patients
decreased signiﬁcantly.
Of the 1644 patients screened, 58 (3.5%) had positive
nasal swabs for MRSA. MSSA was positive in 351 patients.
(21.4%) At the surgical visit, the OR nurse asked about
treatment compliance, and there was a self-reported 96.4%
complianceratewithmupirocinnasaltreatment anda98.8%
compliance rate with chlorhexidine shower.
There were a total of 6 deep infections in the control
group (1.45%) and 21 in the treatment group (1.28%).
All but one of the 27 infections had a positive culture for
at least one microorganism. There was 1 MRSA infection
in the control group (0.24%) and 3 MRSA infections in
the treatment group (0.30%); 1 patient was found to be a
carrier of MRSA on initial PAT and later developed a MRSA
infection postoperatively. Those microorganisms isolated in
addition to Staphylococcus species included Streptococcus
species, Pseudomonas, and E. coli. (See Table 1 ).
4.Discussion
There is evidence that staphylococci colonization is a risk
factor for surgical site infection. Studies have shown that
10%–15% of healthy adults carry Staphylococcus aureus
in their nares; this ﬁgure rises to 20%–35% in hospital
personnel [9]. It has been noted that a high-level of nasal
carriage of Staphylococcus aureus is the most important
and only signiﬁcant risk factor of developing a surgical
site infection [14]. A randomized double-blinded, placebo-
controlled multicenter trial showed a decrease in the rate of
deep surgical site infection of 4.3% to 3.4% from 7.7% with
decolonization of nasal carriers of MSSA [12].
In our patient population, staphylococci decolonization
led to a 13% decrease (P = .809) in deep surgical
site infections. These ﬁndings did not reach statistical
signiﬁcance, but they represented a positive trend towards
the eﬃcacy of a decolonization program in decreasing
infections. The primary weakness of this study was the
small non-PAT control group. When the decolonization
protocolwasﬁrst introducedtherewere a signiﬁcant number
of patients who attended outside clinics for preoperative
clearance. However this control group quickly diminished
as surgeons at our institution realized the utility of PAT
clinic. This fact combined with the already low infection
rate in primary total joint replacement surgery made it
impossible to reach statistical signiﬁcance from one center.
Weperformedapoweranalysisanddeterminedthatasample
size of 57,604 patients in each group would be required
for statistical signiﬁcance given the low rate of infections in
the control group. Another limitation of this study is that
the individual components of the decolonization protocol
(i.e., mupirocin decolonization, chlorhexidine shower, and
prophylactic antibiotics) were not individually tested. We
hypothesize that there is a synergistic beneﬁt to each of these
steps, butfurther studieswould beneeded to determine their
individual eﬀect on the primary outcome.
Despite its limitations, to our knowledge, this is the
largest study on the eﬀect of a decolonization protocol with
mupirocin in an elective orthopaedic population. A similar
study in the Orthopaedic trauma literature identiﬁed riskArthritis 3
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Figure 1: MRSA/MSSA screening and treatment protocol.
Table 1
# Patients Deep SSIs Percentage MRSA infections Percentage
Control 414 6 1.45% 1 16.6%
Treatment 1644 21 1.28% 3 14.3%
Totals 2058 27 1.31% 4 14.8%
factors associated with MRSA infections but had a baseline
infection rate that was doubled that of typical total joint
surgery [15]. One should use caution when applying the
results of the trauma literature to elective primary joint
replacement surgery [1, 15, 16]. To date the evidence for
the eﬀectiveness of staphylococcus decolonization protocols
to decrease infection in total joint patients has been split.
Several level III studies conclude that there is a beneﬁt
to staphylococcus decolonization in elective orthopaedic
surgery, while one level I study refutes it [13, 17, 18]. One
study looked at 1495 consecutive patients who underwent
total joint replacement in a 2 years period compared to a
historical control and concluded that the nasal decoloniza-
tion for S. aureus resulted in a fourfold decrease in S. aureus
surgical site infections for patients colonized with S. aureus
[18]. The only randomized, double-blinded, and placebo-
controlled study of the use of mupirocin in an elective
orthopaedic population yielded mixed results [11]. They
found a ﬁvefold lower rate of SSIs caused by S. aureus in the
mupirocin group compared to placebo; however, there was
also a much higher rate of deep SSIs in the treatment group
compared to placebo [11]. It should be noted that all were
single-center studies and did not have large enough sample
sizes to yield statistical signiﬁcance.
5.Conclusion
The role ofmupirocin in the elective orthopaedicpopulation
has not been well studied. At this time, there is no evidence
that decolonization will reduce the deep infection rate or
overall surgical site infection rate. Althoughthis is the largest
retrospective review of the eﬀect of MRSA decolonization
on infection in total joint surgery, it is underpowered to
reach any signiﬁcant ﬁndings. Due to the low rate of
infections in primary total knee and hip surgeries, it is
impossible for any single institution to enroll a suﬃcient
number of patients for trends to reach statistical signiﬁcance
[4, 19, 20]. Two large double-blinded, randomized studies
of general surgery patients compared analogous mupirocin
decolonization protocols to placebo and concluded that
there is a signiﬁcant decrease in the rate of nosocomial
infections among high-risk patients with nasal carriage of
S. aureus [3, 12]. Additionally, there was a clear costeﬀective
beneﬁt for decolonization of those patients colonized with4 Arthritis
MRSA [12]. Our group recently published ﬁndings on the
costeﬀectiveness of a Staphylcoccus screening and decolo-
nization protocol in the high-risk Orthopaedic patients [21].
We reported that only a modest reduction in the surgical
site infection rate was necessary to be cost savings to the
hospital. The trend we observed in this study although not
statistically signiﬁcant wouldclearly beﬁnancially signiﬁcant
[21]. It is the authors’ opinion that with a suﬃciently
large elective orthopaedic population, similar results and
conclusions would be reached. Our ﬁndings in this study
add to a growing body of evidence that the decolonization of
S. aureus decreased surgical infections. Clinicians may want
to consider preoperative decolonization given the risk and
signiﬁcant consequences of infection.
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